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HES-1 Is Involved in Adaptation of Adult Human -Cells
to Proliferation In Vitro
Yael Bar, Holger A. Russ, Sarah Knoller, Limor Ouziel-Yahalom, and Shimon Efrat
OBJECTIVE—In vitro expansion of -cells from adult human
islets could solve the tissue shortage for cell replacement therapy
of diabetes. Culture of human islet cells typically results in 16
cell doublings and loss of insulin expression. Using cell lineage
tracing, we demonstrated that the expanded cell population
included cells derived from -cells. Understanding the molecular
mechanisms involved in -cell fate in vitro is crucial for optimiz-
ing expansion and redifferentiation of these cells. In the devel-
oping pancreas, important cell-fate decisions are regulated by
NOTCH receptors, which signal through the hairy and enhancer
of split (HES)-1 transcriptional regulator. Here, we investigated
the role of the NOTCH signaling pathway in -cell dedifferenti-
ation and proliferation in vitro.
RESEARCH DESIGN AND METHODS—Isolated human islets
were dissociated into single cells. -Cells were genetically la-
beled using a Cre-lox system delivered by lentiviruses. Cells were
analyzed for changes in expression of components of the NOTCH
pathway during the initial weeks in culture. HES-1 expression
was inhibited by a small hairpin RNA (shRNA), and the effects on
-cell phenotype were analyzed.
RESULTS—Human -cell dedifferentiation and entrance into
the cell cycle in vitro correlated with activation of the NOTCH
pathway and downregulation of the cell cycle inhibitor p57.
Inhibition of HES-1 expression using shRNA resulted in signiﬁ-
cantly reduced -cell replication and dedifferentiation.
CONCLUSIONS—These ﬁndings demonstrate that the NOTCH
pathway is involved in determining -cell fate in vitro and suggest
possible molecular targets for induction of -cell redifferentiation
following in vitro expansion. Diabetes 57:2413–2420, 2008
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eplacement of -cells by transplantation is a
promising approach for treatment of type 1
diabetes; however, its application on a large
scale is limited by the availability of pancreas
donors. In a normal adult pancreas, a slow rate of -cell
renewal is responsible for maintenance of an adequate
functional -cell mass. This rate is accelerated in condi-
tions of increased demands for insulin, such as pregnancy
(1) and obesity (2). Work in an animal model demon-
strated that new -cells are generated in adult mice
predominantly by replication of preexisting -cells rather
than by neogenesis from insulin-negative stem/progenitor
cells (3). This ﬁnding has raised hopes for recapitulation of
-cell expansion in cultures of adult human islets. How-
ever, previous attempts at in vitro expansion of adult
human -cells resulted in a limited number of cell popu-
lation doublings and loss of insulin expression (4–7).
Insulin-negative cells with a considerable proliferative
capacity were derived from cultured human islets (8–10).
Insulin expression in these cells could be induced by
changing the culture conditions; however, its levels were
low and varied among donors (8–10). One possible inter-
pretation of these results is that -cells survive, dediffer-
entiate, and divide in culture. Recently, we applied a
genetic cell lineage tracing approach for labeling cultured
adult human islets and demonstrated that, in contrast to
mouse -cells (11–14), dedifferentiated, label-positive cells
derived from human -cells could be induced to signiﬁ-
cantly proliferate in vitro (15). These cells may be of value
for development of cell therapy for type 1 diabetes, since
they may retain some -cell–speciﬁc chromatin structure
to allow their redifferentiation. Understanding the molec-
ular mechanisms involved in -cell dedifferentiation and
replication in vitro may facilitate the expansion and redif-
ferentiation of these cells.
In the developing pancreas, important cell-fate deci-
sions, including the switch from proliferation to differen-
tiation, and the choice between exocrine and endocrine
fates (16), as well as among different endocrine fates
(17–19), are regulated by the NOTCH signaling pathway.
Expression of NOTCH ligands on a differentiating cell
inhibits development of the same phenotype in neighbor-
ing cells, in a mechanism termed lateral inhibition (16).
Ligand binding to NOTCH receptors on a neighboring cell
results in cleavage of the NOTCH intracellular domain
(NICD), which enters the nucleus and forms a complex
that modulates gene expression (20). The hairy and en-
hancer of split (HES) family of transcriptional regulators is
a major target of the NICD complex. In fetal pancreata,
HES-1 acts as an inhibitor of neurogenin 3 (NGN3) gene
expression, which is required for islet development (21).
In addition, HES-1 regulates the cell cycle by inhibiting
expression of genes encoding the cyclin kinase inhibitors
p27 and p57 (22,23). Some evidence suggests that it may
also inhibit insulin gene expression (17). Overall, HES-1 is
associated with promoting cell replication and preventing
cell differentiation. Forced expression of NOTCH inhibits
pancreas cell differentiation (17,18), while mice with null
mutations in genes encoding NOTCH pathway compo-
nents exhibit accelerated differentiation of endocrine pan-
creas (16,21). The NOTCH pathway is not normally
expressed in the adult pancreas; however, it is activated in
conditions associated with cell dedifferentiation and rep-
lication, such as regeneration following experimental pan-
creatitis (24), pancreatic neoplasia (25), metaplasia of
cultured pancreatic exocrine cells (26), and in rat -cells
exposed to cytokines (27).
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trance into the cell cycle in vitro involve induction of the
NOTCH pathway. Our ﬁndings demonstrate a considerable
activation of the NOTCH pathway in these cells, which
correlates with downregulation of the cell cycle inhibitor
p57 and loss of insulin expression. Inhibition of HES-1
expression using small hairpin RNA (shRNA) results in
reduced replication of cultured -cells and a decrease in
cell dedifferentiation. These ﬁndings suggest possible mo-
lecular targets for prevention of -cell dedifferentiation in
culture or induction of cell redifferentiation following in
vitro expansion.
RESEARCH DESIGN AND METHODS
Islet cell culture. Islets were received 2–3 days following isolation. Islets
from individual donors were dissociated into single cells and cultured in
CMRL-1066 medium containing 5.6 mmol/l glucose and supplemented with
10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 g/ml streptomycin,
100 g/ml gentamicin, and 5 g/ml amphotericine B as described (8). The
cultures were refed twice a week and split 1:2 once a week.
HES-1 inhibition and lineage tracing. HES1 shRNAs (accession nos. TRCN
18989, 18990, 18991, and 18993) and a nontarget shRNA, cloned in pLKO.1
lentiviral vector, were obtained from the RNAi Consortium (Sigma-Aldrich).
Virus was produced in 293T cells following cotransfection with the pCM-
VdR8.91 and pMD2.G packaging plasmids. The culture medium was harvested
48 h later. Islet cells cultured for 1–2 days were washed with PBS and infected
at multiplicity of infection 2.5:1 in CMRL-1066 medium containing 8 g/ml
polybrene overnight. The medium was then replaced with regular culture
medium. Four days after infection, the cells were selected for puromycin
resistance (1 g/ml) for 3 days. Two weeks after infection, the cells were
harvested for further analysis. For -secretase inhibition, 5 mol/l of L-685,458
(Calbiochem) were added to cells at passage 2 (P2) for 17 h. Lineage tracing
was performed using the RIP-Cre and pTrip cytomegalo virus (CMV)-loxP-
DsRed2-loxP–enhanced green ﬂuorescent protein (eGFP) viruses as de-
scribed (15). Brieﬂy, islet cells cultured for 1–2 days were infected with a 1:1:1
mixture of the three viruses (shRNA plus RIP-Cre plus pTrip CMV-loxP-
DsRed2-loxP-eGFP) at a total multiplicity of infection 4:1. Selection and
further analysis were carried out as described above.
RNA analyses. Total RNA was extracted using a High Pure RNA isolation kit
(Roche). cDNA was synthesized using SuperScript III (Invitrogen). qPCR was
performed using a Prism 7300 ABI Real-Time PCR System (Applied Biosys-
tems). The Assay-On-Demand (Applied Biosystems) TaqMan ﬂuorogenic
probes that were used in this study are listed in Table 1. Relative quantitative
analysis was performed according to the comparative computed tomography
method by using the arithmetic formula 2
(ct). The cDNA levels were
normalized to human ribosomal protein P0 cDNA.
Immunoﬂuorescence. Cells were plated in 24-well plates on sterilized
coverslips and ﬁxed in 4% paraformaldehyde. Cells were permeabilized with
0.25% NP40 for 10 min and blocked for 10 min at room temperature in 1% BSA,
10% FBS, and 0.2% saponin. Cells were then incubated with the following
primary antibodies diluted in blocking solution overnight at 4°C: mouse
anti-insulin (1:1,000; Sigma-Aldrich), rabbit anti-p57 (1:500; Santa Cruz), rabbit
anti–HES-1 (1:1,000; Chemicon), mouse anti-Ki67 (1:200; Zymed), rabbit anti-Ki67
(1:50; Zymed), mouse anti–bromo-deoxyuridine (BrdU) (1:20), rabbit anti-
NICD (1:10; Cell Signaling), mouse anti–green ﬂuorescent protein (1:500;
Chemicon), and rabbit anti-GFP (1:1,000; Invitrogen). The bound antibody was
visualized with a ﬂuorescent secondary antibody (anti-mouse or anti-rabbit
AMCA [1:200; Jackson], anti-mouse or anti-rabbit Cy3 [1:200; Biomeda], and
anti-mouse or anti-rabbit Alexa Fluor 488 [1:200; Molecular Probes]) under a
Zeiss confocal microscope. The speciﬁcity of the primary antibodies was
demonstrated using FDC human colon ﬁbroblast cells (data not shown). The
speciﬁcity of the rabbit anti–HES-1 antibody from Chemicon was determined
using LAN-5 human neuroblastoma cells as a negative control and human
bone marrow mesenchymal stem cells as a positive control. The lack of HES-1
expression in LAN-5 cells and its presence in bone marrow mesenchymal stem
cells were demonstrated using immunoblotting with a different HES-1 anti-
body (see below). Lack of HES1 mRNA in LAN-5 cells was previously reported
(28). Nuclei were visualized by staining with DAPI (Roche) for 5 min at room
temperature. BrdU staining was performed following a 24-h labeling period as
previously described (29).
Immunoblotting. Total cellular protein was extracted in 0.5% NP40 contain-
ing a protease inhibitor cocktail (Roche). Protein concentration was deter-
mined by the bicinchoninic acid method (Pierce, Rockford, IL). A total of 70
g protein were separated on 12% SDS-PAGE and electroblotted onto
polyvinylidene ﬂuoride membranes. The membranes were incubated with
rabbit anti–HES-1 (1:1,000; a gift from T. Sudo), rat anti–NOTCH-1 (1:100;
DSHB), or rabbit anti–poly (ADP-ribose) polymerase (PARP) (1:1,000; Cell
Signaling). Loading was monitored using goat anti–-actin or mouse anti–heat
shock cognate protein 70 (HSC70) (1:1,000; Santa Cruz). The bound antibody
was visualized with the appropriate horseradish peroxidase–conjugated anti-
IgG (Jackson) and SuperSignal West Pico Chemiluminescent Substrate
(Pierce). Signal intensity was quantitated using TINA software. Cells treated
with 1 mol/l staurosporine for 6 h were used as positive control for the PARP
blot.
Apoptosis assay. Terminal uridine deoxynucleotidyl transferase dUTP nick-
end labeling assay was performed using a Chemicon ApopTag Fluorescein In
Situ Apoptosis Detection Kit according to the instructions of the manufac-
turer. Cells at P0 were stained 24 h following culture initiation. Cells were
costained for insulin as described above.
Insulin content and secretion. Glucose-stimulated insulin secretion and
insulin content were assayed as described (8).
Statistical analysis. Signiﬁcance was determined using Student’s t test. To
approach a normal distribution of the qPCR data, a logarithmic transformation
was performed. To account for multiple testing, the Bonferroni correction was
applied.
RESULTS
Upregulation of HES-1 in cultured human -cells.
Human islets were isolated from nine donors, six males
and three females aged 38–60 years (mean age 50  8),
with a purity ranging between 65 and 85% (mean 78  6%).
Islets from each donor were dissociated and expanded in
culture as described (8). Quantitative RT-PCR (qPCR)
analyses of RNA extracted from these cells during the ﬁrst
2 weeks of culture revealed a rapid dedifferentiation, as
previously reported (8), which was manifested in a drastic
decrease in insulin mRNA levels, averaging 166-fold (P 
8.7 	 10
7 at P2) (Fig. 1A) (see data on cells from
individual donors in online appendix Fig. 1 [available at
http://dx.doi.org/10.2337/db07-1323]). Concomitant with
this decrease, an increase in HES1 mRNA was observed in
cells from all donors, averaging 4.6-fold (P  0.006 at P2)
within the ﬁrst 2 weeks of culture (Fig. 1A). A similar
increase was noted in HES-1 protein levels (Fig. 1B). At
both RNA and protein levels, the wave of HES-1 upregu-
lation peaked within the ﬁrst 2 weeks of culture and was
downregulated thereafter. To demonstrate that HES-1
upregulation in this system was dependent on NOTCH
activation, we used an inhibitor of -secretase, the pro-
tease complex required for generation of NICD (30). As
seen in Fig. 1C, cell incubation with the inhibitor resulted
in 10-fold lower HES-1 levels, supporting a NOTCH-depen-
dent mechanism. Immunostaining could not detect signif-
icant HES-1 expression in nuclei of cells with intense
TABLE 1
Assay-on-Demand (Applied Biosystems) TaqMan ﬂuorogenic
probes used in the study
Gene Probe
DLL1 Hs00194509_m1
HES1 Hs00172878_m1
Insulin Hs00355773_m1
JAG2 Hs00171432_m1
NEUROD1 Hs00159598_m1
NOTCH1 Hs00413187_m1
NOTCH2 Hs01050706_m1
NOTCH3 Hs01128547_m1
NOTCH4 Hs00965897_m1
p57 Hs00175938_m1
PDX1 Hs00426216_m1
RPLP0 Hs99999902_m1
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detected in insulin-negative cells. To monitor HES-1 ex-
pression in dedifferentiated cells derived from -cells,
-cells in freshly isolated islets were heritably labeled
using a cell lineage tracing approach recently developed in
our laboratory (15). The labeling approach is based on cell
infection with a mixture of two lentivirus vectors: one
expressing Cre recombinase under the insulin promoter
(RIP-Cre) and the other a reporter cassette in which the
CMV promoter is separated from an eGFP gene by a
loxP-ﬂanked stop region. Removal of the stop region in
-cells infected by both viruses activates eGFP expression
speciﬁcally in these cells, thereby allowing continuous
tracking of -cell fate after insulin expression is lost.
Residual insulin expression in -cells during the initial
days in culture provides a sufﬁcient window of time for
RIP-Cre expression and eGFP activation. Using this
method, 57.5  8.9% of insulin-positive cells were labeled
with eGFP (15). Analysis of the cells expanded in culture
following labeling revealed HES-1 staining in cells that lost
insulin expression but maintained eGFP expression, dem-
onstrating that they were derived from -cells (Fig. 1D). A
total of 89.3  0.1% of eGFP

 insulin-negative cells were
HES-1

 (based on counting 200 cells in cultures from
each of three donors).
Changes in expression of components of the NOTCH
pathway in cultured human -cells. qPCR analyses
revealed changes in levels of transcripts encoding the four
members of the NOTCH family. NOTCH1 transcripts were
upregulated on average by 3.6-fold within the ﬁrst 2 weeks
of culture (P  0.02 at P2) (Fig. 2A). A similar increase was
detected in the NOTCH1 120-kd transmembrane fragment
(Fig. 2B), paralleling the changes in HES-1 levels (Fig. 1B).
NOTCH2 and NOTCH3 were signiﬁcantly upregulated on
average by 9.7-fold (P  8.8 	 10
5 at P2) and 10.1-fold
(P  1.0 	 10
4 at P2), respectively, within the ﬁrst 2
weeks of culture. Overall, the activation of NOTCH1–3
paralleled that of HES-1. In contrast, NOTCH4 was dras-
tically downregulated, on average 50-fold (P  3.0 	 10
5
at P2) from its level in primary islets. As with HES1
upregulation, NOTCH1–3 upregulation peaked within the
ﬁrst 2 weeks of culture and was downregulated thereafter.
Transcripts encoding presenilin-1, a component of the
-secretase complex, and recombination signal-binding
protein 1 for J- (RBPJK), a protein that participates in the
NICD nuclear complex, were not signiﬁcantly changed in
the cultured cells (data not shown). In contrast, tran-
scripts for NOTCH ligands were downregulated during the
initial weeks of culture (Fig. 2A). DELTA1 transcripts
were downregulated on average 3.3-fold (P  1.4 	 10
4
at P2) within the ﬁrst 2 weeks of culture. JAG1 tran-
scripts were not signiﬁcantly changed (data not shown).
JAG2 transcripts were downregulated on average 5.5-
fold (P  1.9 	 10
5 at P2) within the ﬁrst 2 weeks of
culture. The increased activity of the NOTCH pathway
was manifested by appearance of NICD in cell nuclei, as
revealed by immunostaining (Fig. 2C). Similar to the
pattern of HES-1 immunostaining, staining for NICD
could not be detected in cells intensely stained for
insulin. NICD staining was detected in all (100%) lin-
eage-labeled, insulin-negative cells identiﬁed as origi-
nating from -cells by eGFP expression (Fig. 2C) (based
on counting 200 cells in cultures from each of three
donors).
Changes in expression of cell cycle inhibitors. To
evaluate the consequences of increased HES-1 expression
in the cultured islet cells, we analyzed changes in tran-
scripts of genes encoding cyclin kinase inhibitors, which
are among the main targets of repression by HES-1 (22,23).
Transcripts encoding p57, which is thought to be the main
cell cycle inhibitor in human -cells (22), were downregu-
lated, on average, 2.9-fold (P  0.004 at P2) within the ﬁrst
2 weeks of culture (Fig. 3A). A further reduction was
observed at P3, averaging 7.1-fold, compared with P0 (P 
0.002). This ﬁnding was supported by immunostaining for
p57, which showed its presence in all (100%) lineage-
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FIG. 1. Upregulation of HES-1 in cultured human islet cells and eGFP

cells derived from -cells correlates with downregulation of insulin. A:
qPCR analysis of RNA extracted from islet cells derived from nine
donors. P indicates passage number and weeks in culture. RQ indicates
relative quantiﬁcation compared with P0, which represents islet cells
at culture initiation. Data are means  SD (n  9). Asterisks indicate
statistical signiﬁcance, compared with P0 (P < 3.3  10
5 for insulin
and P < 0.006 for HES1). The increase in HES1 mRNA levels at P1 was
marginally signiﬁcant (P  0.06). B: Immunoblotting for HES-1 in
protein extracted from islet cells at the indicated passage number.
-Actin served as a loading control. C: Immunoblotting for HES-1 in
protein extracted from islet cells at P2, following a 17-h incubation
with the -secretase inhibitor L-685458. HSC70 served as a loading
control. D: Immunoﬂuorescence analysis of islet cells (left panel) and
eGFP
 cells derived from -cells (right panel) following 10 days in
culture. The left panel is merged with a phase contrast image. Arrow
points to a -cell that still expresses insulin and is not labeled for
HES-1. eGFP is detected in both cytoplasm and nucleus. Bar  20 m.
(Please see http://dx.doi.org/10.2337/db07-1323 for a high-quality digi-
tal representation of this ﬁgure.)
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 cells and its absence in all
(100%) insulin-negative eGFP

 cells (based on counting
200 cells in cultures from each of three donors) (Fig.
3B). In contrast to p57, transcripts for p21 were upregu-
lated in cells from all donors, and those for p27 varied
considerably among donors (data not shown). The down-
regulation of p57 transcripts and protein correlated with
cell entrance into the cell cycle, as manifested by Ki67
staining in p57-negative eGFP

 cells (Fig. 3C). The nuclear
area of replicating cells was 2.5- to 4-fold larger than that of
insulin-positive cells, as previously reported (8). The increase
in cell size is likely associated with recruitment of quiescent
-cells into the cell cycle (31).
Inhibition of HES-1 expression prevents induction of
-cell replication. To further correlate the induction of
-cell replication with HES-1 upregulation, HES-1 induction
during the initial weeks of culture was inhibited using
shRNA. Following screening of four HES1 shRNA sequences
for activity in 293T cells, one of four (TRCN18993) was
selected as most efﬁcient, based on reduction in HES-1
protein levels, as analyzed by immunoblotting (data not
shown). Isolated human islets were dissociated, and the
cells were infected with a lentivirus encoding HES1
shRNA before culture under standard conditions. Selec-
tion for drug resistance allowed elimination of uninfected
cells. Cells infected with a nontarget shRNA lentivirus and
selected under similar conditions served as control. As
seen in Fig. 4A, cell infection with the HES1 shRNA virus
resulted in up to six-times-lower HES-1 protein levels,
compared with cells infected with the control virus. The
lower HES-1 levels were associated with a diminished cell
proliferation compared with cells infected with the control
vector, as judged by staining for BrdU incorporation (Fig.
4B). In addition, staining for Ki67 in eGFP

 cells demon-
strated a lower replication rate among cells derived from
-cells (Fig. 4B). The reduced replication in cells infected
with the HES1 shRNA virus did not correlate with an
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FIG. 2. Upregulation of the NOTCH pathway in cultured human islet
cells and eGFP
 cells derived from -cells. A: qPCR analysis of RNA
extracted from islet cells derived from eight donors at the indicated
passage numbers. P indicates passage number and weeks in culture. RQ
indicates relative quantiﬁcation compared with P0. Data are means 
SD (n  8). Asterisks indicate statistical signiﬁcance, compared with
P0 (P < 0.03 for NOTCH1; P < 0.04 for NOTCH2; P < 9  10
4 for
NOTCH3; P < 0.03 for NOTCH4; P < 0.005 for DLL1; P < 0.026 for
JAG2). The increase in NOTCH3 mRNA levels at P3 was marginally
signiﬁcant (P  0.06). B: Immunoblotting for NOTCH1 120-kd trans-
membrane fragment in protein extracted from islet cells at the indi-
cated passage number. HSC70 served as a loading control. C:
Immunoﬂuorescence analysis of islet cells (left panel) and eGFP
 cells
derived from -cells (right panel) following 10 days in culture. Bar 
20 m. (Please see http://dx.doi.org/10.2337/db07-1323 for a high-
quality digital representation of this ﬁgure.)
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FIG. 3. Downregulation of p57 in cultured human islet cells and eGFP

cells derived from -cells. A: qPCR analysis of RNA extracted from islet
cells derived from eight donors at the indicated passage numbers. P
indicates passage number and weeks in culture. RQ indicates relative
quantiﬁcation compared with P0. Data are means  SD (n  8). Stars
indicate statistical signiﬁcance, compared with P0 (P < 0.03). B and C:
Immunoﬂuorescence analysis of eGFP
 cells derived from -cells fol-
lowing 10 days in culture. Solid arrow in B points to an eGFP
 cell
that has lost both insulin and p57 expression; dashed arrow points
to an eGFP
 -cell that maintains both insulin and p57 expression.
Arrow in C points to an eGFP
 cell that maintains p57 expression
and is not labeled for Ki67. Bar  20 m. (Please see http://dx.doi.
org/10.2337/db07-1323 for a high-quality digital representation of
this ﬁgure.)
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analysis for cleaved PARP (Fig. 4C). In addition, terminal
uridine deoxynucleotidyl transferase dUTP nick-end label-
ing assay did not detect signiﬁcant changes between cells
at P2 treated with either virus and cells at P0 among
insulin-expressing cells or the total cell population (aver-
aging 1.41, 2.19, and 1.64% apoptotic cells among insulin-
positive cells at P0, P2 cells treated with HES1 shRNA, and
P2 cells treated with nontarget virus, respectively, based on
counting 500 cells in cultures from each of three donors). The
reduced proliferation of cells infected with the HES1 shRNA
virus correlated with a 5.7-fold (P0.001) higher level of p57
transcripts, compared with those in cells infected with the
control virus (Fig. 4D) (see data on cells from individual
donors in online appendix Fig. 2). The levels of p57 tran-
scripts obtained with HES1 shRNA were 3.3-fold higher (P 
0.04) compared with P0. The reduced HES-1 levels did not
signiﬁcantly affect the levels of NOTCH transcripts, which is
consistent with the position of HES-1 downstream of NOTCH
in the pathway (Fig. 4D).
Inhibition of HES-1 expression reduces -cell dedif-
ferentiation. The lower HES-1 levels in cells expressing
HES1 shRNA resulted in a reduced rate of cell dedifferen-
tiation, as manifested by higher levels of transcripts en-
coding differentiated -cell markers. Thus, levels of insulin
transcripts were 6.6-fold higher (P  5.5 	 10
4) com-
pared with cells infected with the control virus (Fig. 5A).
Similarly, transcript levels for the -cell transcription
factors PDX1 and NEUROD1 were 4.4-fold (P  0.005) and
3.3-fold (P  0.004) higher, respectively, in cells express-
ing HES1 shRNA (Fig. 5A). The levels of PDX1 and
NEUROD1 transcripts in cells expressing HES1 shRNA
were 0.52 and 0.54 of those in primary islets, respectively.
In contrast, the levels of insulin transcripts in cells ex-
pressing HES1 shRNA were ninefold lower compared with
those in primary islets. In agreement with the higher
insulin mRNA levels, insulin immunostaining detected a
fourfold (P  0.016) higher number of insulin-positive
cells in cultures expressing HES1 shRNA compared with
those treated with the control virus (Fig. 5B). The fraction
of insulin-positive cells among eGFP

 cells was also
threefold higher in the presence of HES1 shRNA, indicat-
ing that fewer -cells underwent dedifferentiation (Fig. 5B
and C). Insulin content in cells expressing HES1 shRNA
was 3.5-fold higher (P  0.03) compared with cells treated
with the control virus (Fig. 6A), although these levels were
14-fold lower compared with intact islets before trypsiniza-
tion. Cells at P2 maintained the same two- to threefold
increase in insulin secretion in response to glucose ob-
served in intact islets (Fig. 6B). However, insulin secretion
from cells expressing HES1 shRNA was 6.8-fold higher
(P  0.006) compared with cells treated with the control
virus, in response to 16 mmol/l glucose (Fig. 6B). Never-
theless, cells expressing HES1 shRNA secreted a much
higher fraction of their insulin content (15.5%), compared
with intact islets (3.9%), during a 30-min assay. (Cells
infected with the nontarget virus secreted 19.7% of their
content.)
To verify that these results were due to speciﬁc
inhibition of HES-1 expression, the studies were repro-
duced with two additional HES1 shRNAs, TRCN18990
and TRCN18991. As seen in Fig. 7A, cell infection with
viruses encoding these shRNAs resulted in reduction in
cellular HES-1 protein levels. The reduction in HES-1
correlated with 5.3-fold (P  3.3 	 10
5) and 2.2-fold
(P  6.6 	 10
4) higher levels of p57 transcripts in cells
expressing the two HES1 shRNAs, respectively, com-
pared with the levels in cells infected with the nontarget
virus. The levels of insulin transcripts were 3.4-fold (P 
1.3 	 10
5) and 1.9-fold (P  2.8 	 10
4) higher,
respectively. The levels of PDX1 transcripts were 4.0-
fold (P  9.2 	 10
5) and 2.5-fold (P  1.9 	 10
4)
higher, respectively, and the levels of NEUROD1 tran-
scripts were 7.7-fold (P  3.5 	 10
5) and 3.1-fold (P 
8 	 10
6) higher, respectively. These results are com-
parable with those obtained using HES1 shRNA
TRCN18993, indicating that the effects on cell prolifer-
ation and differentiation were caused by speciﬁc inhibi-
tion of HES-1 expression.
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FIG. 4. Prevention of HES-1 upregulation by shRNA reduces replica-
tion of cultured human islet cells and eGFP
 cells derived from -cells.
A: Immunoblotting for HES-1 in protein extracted from islet cells
following infection with HES1 shRNA TRCN18993 or nontarget virus.
-Actin served as a loading control. B: Top panel: Incidence of BrdU

cells among cultured islet cells following infection with HES1 shRNA
TRCN18993 or nontarget virus. Data are means  SD (n  3 donors;
>1,000 cells counted in culture from each donor; P  0.02). Bottom
panel: Incidence of Ki67
 cells among eGFP
 cells from two represen-
tative donors following infection with HES1 shRNA or nontarget virus.
Data are based on >1,000 cells counted in culture from each donor. ,
G13; f, I10. C: Immunoblotting for PARP in protein extracted from
islet cells following infection with nontarget (lane 3)o rHES1 shRNA
TRCN18993 virus (lane 4). Uninfected cells incubated with (lane 1)o r
without (lane 2) the apoptotic agent staurosporin served as controls.
The lower band in lane 1 represents cleaved PARP. -Actin served as a
loading control. D: qPCR analysis of RNA extracted from islet cells
following infection with HES1 shRNA TRCN18993 or nontarget virus.
RQ indicates relative quantiﬁcation compared with P0. Data are
means  SD (n  3 donors). Only the change in p57 is signiﬁcant (P 
0.001 vs. cells infected with nontarget virus, indicated by star). f, P0;
, nontarget;
￿
￿ , HES1 shRNA. All the analyses were done 14 days
following viral infection.
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Our ﬁndings demonstrate that culture of dissociated adult
human islet cells in serum-containing medium, which
induces -cell dedifferentiation and replication, involves
activation of elements of the NOTCH pathway. Transcript
levels for NOTCH1–3 and HES1 are upregulated. In con-
trast, transcripts for NOTCH4, and the NOTCH ligands
DELTA1 and JAG2, are downregulated. These changes
were initially observed in a mixed population of islet cells,
which likely included contaminating duct and exocrine
cells. Using virus-mediated cell lineage tracing, we then
determined that these changes occurred in -cells. The
upregulation of the NOTCH pathway correlated with cell
dedifferentiation, as manifested by a dramatic decrease in
insulin transcripts, and by cell entrance into the cell cycle,
as manifested by downregulation of p57 transcripts and an
increase in Ki67 staining. The ﬁndings at the RNA level
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FIG. 5. Prevention of HES-1 upregulation by shRNA reduces -cell
dedifferentiation. A: qPCR analysis of RNA extracted from islet cells
following infection with HES1 shRNA TRCN18993 or nontarget virus.
RQ indicates relative quantiﬁcation compared with P0. Data are
means  SD (n  3 donors). The changes in all three genes in cells
infected with HES1 shRNA, compared with cells infected with nontar-
get virus, were signiﬁcant (P < 0.004). f, P0; , nontarget;
￿
￿ , HES1
shRNA. B: Left: Incidence of insulin-positive cells among cultured islet
cells following infection with HES1 shRNA TRCN18993 or nontarget
virus. Data are means  SD (n  3 donors; >1,000 cells counted in
culture from each donor; P  0.016). Right: Incidence of insulin-
positive cells among eGFP
 -cells from two representative donors
following infection with HES1 shRNA or nontarget virus. Data are
based on >1,000 cells counted in culture from each donor. Signiﬁcant
differences compared with nontarget are indicated by stars. , G13; f,
I10. C: Immunoﬂuorescence analysis of insulin in eGFP
 cells follow-
ing infection with HES1 shRNA TRCN18993 or nontarget virus. Bar 
100 m. All the analyses were done 14 days following viral infection.
(Please see http://dx.doi.org/10.2337/db07-1323 for a high-quality digi-
tal representation of this ﬁgure.)
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FIG. 6. HES1 shRNA reduces the decrease in insulin content and
glucose-stimulated insulin secretion observed during dedifferentiation
of cultured islet cells. A: Insulin content in cells infected with HES1
shRNA TRCN18993 or nontarget virus compared with primary islets.
Data are means  SD (n  3 donors). Asterisks indicate statistical
signiﬁcance (P  0.03). B: Insulin secretion in response to glucose
during a 30-min assay. Data are means  SD (n  3 individual
experiments from a representative donor). Asterisk indicate statisti-
cal signiﬁcance of the difference between 0 and 16 mmol/l glucose in
each cell type (P < 0.04). f, 0 mmol/l; , 16 mmol/l.
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FIG. 7. Effects of HES1 shRNAs TRCN18990 and TRCN18991 on gene
expression in cultured islet cells. A: Immunoblotting for HES-1 in
protein extracted from islet cells 14 days following infection with
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￿
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a negative correlation between the presence of HES-1 or
NICD in the nucleus and insulin expression in eGFP

 cells,
which marked their origin from -cells. These in situ
analyses also detected a positive correlation between p57
and insulin expression, conﬁrming the view that -cell
replication involves dedifferentiation.
The key role of HES-1 in these events was revealed by
inhibiting its upregulation with shRNA. In these cells, the
decrease in p57 was prevented and cell proliferation was
greatly reduced. While cell dedifferentiation was not com-
pletely prevented, it was signiﬁcantly inhibited compared
with cells in which HES-1 upregulation was not repressed.
This was manifested by higher levels of insulin transcripts
and fraction of cells immunostaining for insulin, as well as
transcripts encoding -cell transcription factors. In addi-
tion, loss of insulin content and secretion was less pro-
nounced. These ﬁndings suggest that a partial cell
dedifferentiation is independent of HES-1 activity and cell
replication; however, induction of advanced dedifferenti-
ation and cell replication requires HES-1 upregulation.
This interpretation is supported by the ﬁnding that the
bulk of decrease in insulin mRNA occurs during the ﬁrst
week, thus preceding the peak in HES-1 mRNA levels. It is
therefore possible that loss of most of the insulin content
is a precondition for -cell entrance into cell cycle in vitro.
Given the fact that upregulation of the NOTCH pathway
in islet cell cultures followed cell dissociation into single
cells, it is unlikely that it was trigerred by a cell-associated
ligand, as in the lateral inhibition model (16). Rather, it is
possible that this pathway is activated in response to
soluble serum components, as was demonstrated in a
number of cultured cell types (32). This possibility is
supported by our ﬁndings of decreased expression of
NOTCH ligands in islet cell cultures concomitant with
HES-1 upregulation. This is reminiscent of the low levels
of NOTCH ligands in the embryonic pancreas cells ex-
pressing HES-1, which are directed for further prolifera-
tion rather than differentiation (16).
Among the four members of the NOTCH family that
were analyzed, NOTCH1, NOTCH2, and NOTCH3 tran-
scripts were upregulated, while NOTCH4 transcripts were
greatly downregulated. While expression of NOTCH1 and
NOTCH2 was implicated in islet development, NOTCH3
and NOTCH4 expression was documented in mesen-
chymal and endothelial cells (21). Downregulation of
NOTCH4 may reﬂect the elimination of a NOTCH4


subpopulation, which is present in the original islet cell
suspension but for some reason is not maintained in
continuous culture.
The wave of HES-1 upregulation peaked within the ﬁrst
2 weeks of culture and was downregulated thereafter.
Nevertheless, the effects of HES-1 were not reversed, as
manifested by continuous replication of cells derived from
dedifferentiated -cells for up to 16 population doublings
(8,15). The levels of p57 and insulin transcripts did not
rebound thereafter, suggesting that their reinduction re-
quires other signals in addition to the decrease in the
inhibitory effect of HES-1. This ﬁnding suggests a transient
role of HES-1 upregulation that is limited to the initial
adaptation of islet cells to culture, after which cell repli-
cation may continue in the presence of the lower HES-1
levels found in nonreplicating cells.
In summary, our ﬁndings provide evidence for activa-
tion of the NOTCH pathway in adult cells and offer an in
vitro model system for studying interactions within this
pathway. In addition, the ﬁndings emphasize the role of
components of the NOTCH pathway in the transition of
quiescent -cells into a dedifferentiated, proliferative state
in vitro. Our ﬁndings demonstrate a negative correlation
between replication and maintenance of differentiated
function in cultured -cells, suggesting that signiﬁcant cell
expansion inevitably involves dedifferentiation and will
require the development of methods for cell redifferentia-
tion following expansion. Components of the NOTCH
pathway may represent molecular targets for induction of
redifferentiation of the expanded cells.
ACKNOWLEDGMENTS
Human islets were provided by the Cell Isolation and
Transplantation Center at the University of Geneva School
of Medicine and San Raffaele Hospital, Milan, Italy,
through the European Consortium for Islet Transplanta-
tion “Islets for Research” distribution program, sponsored
by the Juvenile Diabetes Research Foundation award
6-2005-1178, and by the Diabetes Cell Therapy unit, Fac-
ulty of Medicine, Lille 2 University. This work was sup-
ported by grants from the Israel Science Foundation and
Juvenile Diabetes Research Foundation (to S.E.).
We thank T. Sudo for anti-HES1 antibody and Ran Elkon
for assistance with statistical analyses.
This work was performed in partial fulﬁllment of the
requirements for a PhD degree of Yael Bar.
REFERENCES
1. Sorenson RL, Brelje TC: Adaptation of islets of Langerhans to pregnancy:
beta-cell growth, enhanced insulin secretion and the role of lactogenic
hormones. Horm Metab Res 29:301–307, 1997
2. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: -Cell
deﬁcit and increased -cell apoptosis in humans with type 2 diabetes.
Diabetes 52:102–110, 2003
3. Dor Y, Brown J, Martinez OI, Melton DA: Adult pancreatic beta-cells are
formed by self-duplication rather than stem-cell differentiation. Nature
429:41–46, 2004
4. Beattie GM, Itkin-Ansari P, Cirulli V, Leibowitz G, Lopez AD, Bossie S,
Mally MI, Levine F, Hayek A: Sustained proliferation of PDX-1
 cells
derived from human islets. Diabetes 48:1013–1019, 1999
5. Beattie GM, Leibowitz G, Lopez AD, Levine F, Hayek A: Protection from
cell death in cultured human fetal pancreatic cells. Cell Transplant
9:431–438, 2000
6. Halvorsen TL, Beattie GM, Lopez AD, Hayek A, Levine F: Accelerated
telomere shortening and senescence in human pancreatic islet cells
stimulated to divide in vitro. J Endocrinol 166:103–109, 2000
7. Beattie GM, Montgomery AM, Lopez AD, Hao E, Perez B, Just ML, Lakey
JR, Hart ME, Hayek A: A novel approach to increase human islet cell mass
while preserving -cell function. Diabetes 51:3435–3439, 2002
8. Ouziel-Yahalom L, Zalzman M, Anker-Kitai L, Knoller S, Bar Y, Glandt M,
Herold K, Efrat S: Expansion and redifferentiation of adult human pancre-
atic islet cells. Biochem Biophys Res Commun 341:291–298, 2006
9. Gershengorn MC, Hardikar AA, Wei C, Geras-Raaka E, Marcus-Samuels B,
Raaka BM: Epithelial-to-mesenchymal transition generates proliferative
human islet precursor cells. Science 306:2261–2264, 2004
10. Lechner A, Nolan AL, Blacken RA, Habener JF: Redifferentiation of
insulin-secreting cells after in vitro expansion of adult human pancreatic
islet tissue. Biochem Biophys Res Commun 327:581–588, 2005
11. Weinberg N, Ouziel-Yahalom L, Knoller S, Efrat S, Dor Y: Lineage tracing
evidence for in vitro dedifferentiation but rare proliferation of mouse
pancreatic -cells. Diabetes 56:1299–1304, 2007
12. Chase LG, Ulloa-Montoya F, Kidder BL, Verfaillie CM: Islet-derived ﬁbro-
blast-like cells are not derived via epithelial-mesenchymal transition from
Pdx-1 or insulin-positive cells. Diabetes 56:3–7, 2007
13. Morton RA, Geras-Raaka E, Wilson LM, Raaka BM, Gershengorn MC:
Endocrine precursor cells from mouse islets are not generated by epithe-
lial-to-mesenchymal transition of mature beta cells. Mol Cell Endocrinol
270:87–93, 2007
14. Atouf F, Park CH, Pechhold K, Ta M, Choi Y, Lumelsky NL: No evidence for
Y. BAR AND ASSOCIATES
DIABETES, VOL. 57, SEPTEMBER 2008 2419mouse pancreatic -cell epithelial-mesenchymal transition in vitro. Diabe-
tes 56:699–702, 2007
15. Russ HA, BarY, Ravassard P, Efrat S: In vitro proliferation of cells derived
from adult human -cells revealed by cell-lineage tracing. Diabetes 57:
1575–1583, 2008
16. Apelqvist A, Li H, Sommer L, Beatus P, Anderson DJ, Honjo T, Hrabe de
Angelis M, Lendahl U, Edlund H: Notch signalling controls pancreatic cell
differentiation. Nature 400:877–881, 1999
17. Hald J, Hjorth JP, German MS, Madsen OD, Serup P, Jensen J: Activated
Notch1 prevents differentiation of pancreatic acinar cells and attenuate
endocrine development. Dev Biol 260:426–437, 2003
18. Murtaugh LC, Stanger BZ, Kwan KM, Melton DA: Notch signaling controls
multiple steps of pancreatic differentiation. Proc Natl Acad SciUSA
100:14920–14925, 2003
19. Greenwood AL, Li S, Jones K, Melton D: Notch signaling reveals develop-
mental plasticity of Pax4(
) pancreatic endocrine progenitors and shunts
them to a duct fate. Mech Dev 124:97–107, 2007
20. Ehebauer M, Hayward P, Arias AM: Notch, a universal arbiter of cell fate
decisions. Science 314:1414–1415, 2006
21. Jensen J, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M,
Kageyama R, Guillemot F, Serup P, Madsen OD: Control of endodermal
endocrine development by Hes-1. Nat Genet 24:36–44, 2000
22. Georgia S, Soliz R, Li M, Zhang P, Bhushan A: p57 and Hes1 coordinate cell
cycle exit with self-renewal of pancreatic progenitors. Dev Biol 298:22–31,
2006
23. Murata K, Hattori M, Hirai N, Shinozuka Y, Hirata H, Kageyama R, Sakai T,
Minato N: Hes1 directly controls cell proliferation through the transcrip-
tional repression of p27Kip1. Mol Cell Biol 25:4262–4271, 2005
24. Jensen JN, Cameron E, Garay MV, Starkey TW, Gianani R, Jensen J:
Recapitulation of elements of embryonic development in adult mouse
pancreatic regeneration. Gastroenterology 128:728–741, 2005
25. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue
CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS, Hruban RH, Ball DW,
Schmid RM, Leach SD: Notch mediates TGF alpha-induced changes in
epithelial differentiation during pancreatic tumorigenesis. Cancer Cell
3:565–576, 2003
26. Rooman I, De Medts N, Baeyens L, Lardon J, De Breuck S, Heimberg H,
Bouwens L: Expression of the Notch signaling pathway and effect on
exocrine cell proliferation in adult rat pancreas. Am J Pathol 169:1206–
1214, 2006
27. Darville MI, Eizirik DL: Notch signaling: a mediator of beta-cell de-
differentiation in diabetes? Biochem Biophys Res Commun 339:1063–1068,
2006
28. Van Limpt VA, Chan AJ, Van Sluis PG, Caron HN, Van Noesel CJ, Versteeg
R: High delta-like 1 expression in a subset of neuroblastoma cell lines
corresponds to a differentiated chromafﬁn cell type. Int J Cancer 105:61–
69, 2003
29. Berkovich I, Efrat S: Inducible and reversible beta-cell autoimmunity and
hyperplasia in transgenic mice expressing a conditional oncogene. Diabe-
tes 50:2260–2267, 2001
30. Schroeter EH, Kisslinger JA, Kopan R: Notch-1 signalling requires ligand-
induced proteolytic release of intracellular domain. Nature 393:304–305,
1998
31. Baserga R: Is cell size important? Cell Cycle 6:814–816, 2007
32. Hirata H, Yoshiura S, Ohtsuka T, Bessho Y, Harada T, Yoshikawa K,
Kageyama R: Oscillatory expression of the bHLH factor Hes1 regulated by
a negative feedback loop. Science 298:840–843, 2002
HES-1 ROLE IN PHENOTYPE OF CULTURED HUMAN -CELLS
2420 DIABETES, VOL. 57, SEPTEMBER 2008